UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 14A

 

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No. )

 

Filed by the Registrant ☒

 

Filed by a party other than the Registrant ☐

 

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material under § 240.14a-12

 

MIRA Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required
   
Fee paid previously with preliminary materials.
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

 

 

 

 
 

 

 

 

 

 

 

 

 


MIRA Pharmaceuticals (NASDAQ:MIRA)
過去 株価チャート
から 6 2024 まで 7 2024 MIRA Pharmaceuticalsのチャートをもっと見るにはこちらをクリック
MIRA Pharmaceuticals (NASDAQ:MIRA)
過去 株価チャート
から 7 2023 まで 7 2024 MIRA Pharmaceuticalsのチャートをもっと見るにはこちらをクリック